These findings suggest that GABBR2 may play a protective role in AD by modulating the non-amyloidogenic pathway of APP processing, which is mediated by ADAM10, thereby reducing the amyloidogenic pathway that involves BACE1. Here, ADAM10 is linked to Alzheimer disease.